Mostrar el registro sencillo del ítem

Facilitating antidepressant-like actions of estrogens are mediated by 5-HT1A and estrogen receptors in the rat forced swimming test

dc.creatorEstrada-Camarena, E.
dc.creatorLópez-Rubalcava, C.
dc.creatorFernández-Guasti, A.
dc.date.accessioned2017-06-30T01:34:34Z
dc.date.available2017-06-30T01:34:34Z
dc.date.issued2006es_ES
dc.identifier1468es_ES
dc.identifier.issn0306-4530es_ES
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/6149
dc.identifier.urihttps://doi.org/10.1016/j.psyneuen.2006.05.001es_ES
dc.language.isoenges_ES
dc.relation31 (8) 905-914 p.es_ES
dc.relationversión del editores_ES
dc.rightsacceso cerradoes_ES
dc.titleFacilitating antidepressant-like actions of estrogens are mediated by 5-HT1A and estrogen receptors in the rat forced swimming testes_ES
dc.typearticlees_ES
dc.contributor.affiliationDirección de Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñíz, México DF, Méxicoes_ES
dc.contributor.emailmonesca_71@yahoo.comes_ES
dc.relation.jnabreviadoPSYCHONEUROENDOCRINOLOGYes_ES
dc.relation.journalPsychoneuroendocrinologyes_ES
dc.identifier.placeInglaterraes_ES
dc.date.published2006es_ES
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñizes_ES
dc.identifier.eissn1873-3360es_ES
dc.identifier.doi10.1016/j.psyneuen.2006.05.001es_ES
dc.description.monthSepes_ES
dc.description.abstractotrodiomaPrevious studies have shown that 17beta-estradiol (E2) induces antidepressant-like actions per se and potentiates those produced by fluoxetine (FLX) in the forced swimming test (FST). The aim of the present work was to explore the participation of serotonin 1A receptors (5-HT1A) and estrogen receptors (ERs) in the antidepressant-like actions of E2, FLX or their combination in the FST. Although all antidepressants reduce behavioral immobility, antidepressants that modulate serotonergic neurotransmission increase swimming behavior whereas those that modulate the catecholaminergic neurotransmission increase climbing behavior. Thus, using this animal model, it is possible to infer which neurotransmitter system is modulating the action of an antidepressant compound. Ovariectomized female Wistar rats were used in all experiments. In the first experiment, an effective dose of E2 (10 microg-rat, -48 h) was combined with several doses (0.5, 1.0 and 2 mg-kg) of RU 58668 (a pure ER antagonist) 48 h previous to the FST. The second experiment evaluated the action of (1 mg-kg, -48 h or -23, -5 and -1 h) WAY 100635 (5-HT1A receptor antagonist) on the antidepressant-like action of FLX (10 mg-kg, -23, -5 and -1 h). In the third experiment, the effect of RU 58668 (2 mg-kg, -48) or WAY 100635 (1 mg-kg, -48 h) on the antidepressant-like action of the combination of a sub-optimal dose of E2 (2.5 microg-rat, -48 h) plus a non-effective dose of FLX (2.5 mg-kg, -23,-5 and -1 h) was evaluated. The results showed that RU 58668, the antagonist to the ER, canceled the antidepressant-like action of E2 in a dose-dependent manner. The antagonist to the 5-HT1A receptor blocked the antidepressant action of FLX only when administered simultaneously with FLX, i.e. -23, -5 and -1 h before the FST. Finally, the administration of both RU 58668, and WAY100635 canceled the antidepressant-like action of the combination of E2-FLX. These results imply that both 5-HT1A receptors and ERs participate in the facilitating actions of E2 on the antidepressant-like action of FLX in the FSTes_ES
dc.subject.kwAnimaleses_ES
dc.subject.kwAgentes antidepresivoses_ES
dc.subject.kwDepresiónes_ES
dc.subject.kwTerapia con medicamentoses_ES
dc.subject.kwEtiologíaes_ES
dc.subject.kwEstradioles_ES
dc.subject.kwAnálogos y derivadoses_ES
dc.subject.kwFarmacologíaes_ES
dc.subject.kwAntagonistas del Estrógenoes_ES
dc.subject.kwEstrogenoses_ES
dc.subject.kwFemeninoes_ES
dc.subject.kwFluoxetinaes_ES
dc.subject.kwEfectos del fármacoes_ES
dc.subject.kwPiperazinases_ES
dc.subject.kwPiridinases_ES
dc.subject.kwRatases_ES
dc.subject.kwRatas Wistares_ES
dc.subject.kwReceptor de Serotonina 5-HT1Aes_ES
dc.subject.kwReceptores de Estrógenoes_ES
dc.subject.kwAntagonistas de la Serotoninaes_ES
dc.subject.kwSerotonina Inhibidores de Captaciónes_ES
dc.subject.kwNataciónes_ES
dc.subject.kwRU 58668es_ES
dc.subject.kwPsicologíaes_ES
dc.subject.kwN-(2 - (4 - (2-metoxifenil)-1-piperazinil) etil)-N-(2-piridinil) ciclohexanocarboxamidaes_ES
dc.subject.koAnimalses_ES
dc.subject.koAntidepressive Agentses_ES
dc.subject.koDepressiones_ES
dc.subject.koDrug therapyes_ES
dc.subject.koEtiologyes_ES
dc.subject.koEstradioles_ES
dc.subject.koAnalogs & derivativeses_ES
dc.subject.koPharmacologyes_ES
dc.subject.koEstrogen Antagonistses_ES
dc.subject.koEstrogenses_ES
dc.subject.koFemalees_ES
dc.subject.koFluoxetinees_ES
dc.subject.koMotor Activityes_ES
dc.subject.koDrug effectses_ES
dc.subject.koPiperazineses_ES
dc.subject.koPyridineses_ES
dc.subject.koRatses_ES
dc.subject.koRats, Wistares_ES
dc.subject.koReceptor, Serotonin, 5-HT1Aes_ES
dc.subject.koReceptors, Estrogenes_ES
dc.subject.koSerotonin Antagonistses_ES
dc.subject.koSerotonin Uptake Inhibitorses_ES
dc.subject.koSwimminges_ES
dc.subject.koPsychologyes_ES
dc.subject.koRU 58668es_ES
dc.subject.koN-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamidees_ES


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem